Skip to main content

Table 3 Sensitivity and Specificity of the single or multiple methylation markers in the diagnosis of NMIBC

From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer

 

% Sensitivity (Se)

% Specificity (Sp)

Diagnosis set (n =272)

 HS3ST2

82.0 (137/167)

21.20 (22/105)

 SEPTIN9

90.4 (151/167)

67.6 (71/105)

 SLIT2

90.4 (151/167)

18.1 (19/105)

 HS3ST2 + SEPTIN9

90.4 (151/167)

72.4 (76/105)

 HS3ST2 + SLIT2

90.4 (151/167)

34.3 (36/105)

 SEPTIN9 + SLIT2

91.0 (152/167)

71.4 (75/105)

 HS3ST2 + SEPTIN9 + SLIT2

90.4 (151/167)

75.2 (79/105)

  1. Note: Performance Se/Sp for either 1/highest Sp with Se > 90 % or 2/highest Sp if no Se > 90 %
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us